Imunon (NASDAQ:IMNN) Given Buy Rating at D. Boral Capital

D. Boral Capital restated their buy rating on shares of Imunon (NASDAQ:IMNN) in a research note published on Monday morning,Benzinga reports. They currently have a $29.00 target price on the stock.

Other equities research analysts also recently issued reports about the company. HC Wainwright decreased their price objective on Imunon from $14.00 to $12.00 and set a “buy” rating for the company in a research report on Monday, November 11th. EF Hutton Acquisition Co. I upgraded shares of Imunon to a “strong-buy” rating in a report on Monday, September 23rd.

Imunon Stock Up 3.3 %

IMNN opened at $0.86 on Monday. The firm has a market capitalization of $12.41 million, a P/E ratio of -0.45 and a beta of 2.14. The stock has a fifty day moving average of $0.92 and a 200-day moving average of $1.14. Imunon has a 12-month low of $0.48 and a 12-month high of $3.65.

About Imunon

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.